Sera Prognostics, Inc. (SERA) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Sera Prognostics, Inc. is a women's health company focused on developing and commercializing blood-based biomarker tests, primarily the PreTRM test, which predicts the risk of preterm birth. The company operates a CLIA-certified laboratory in Salt Lake City, Utah, and utilizes a proprietary proteomics and bioinformatics platform. As of the filing date, the company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Revenue | $29,000 | $42,000 | $53,000 | $265,000 |
| Net Loss | $(7,919,000) | $(7,210,000) | $(24,319,000) | $(28,317,000) |
| Loss Per Share (Basic/Diluted) | $(0.24) | $(0.23) | $(0.74) | $(0.91) |
| Operating Expenses | $8,891,000 | $8,226,000 | $27,265,000 | $31,238,000 |
| Cash & Cash Equivalents | $2,684,000 | $3,880,000 | As of Sept 30, 2024 | |
| Total Cash, Equivalents & Marketable Securities | $74,343,000 | $79,920,000 | ||
| Accumulated Deficit | $(271,215,000) | $(246,896,000) | As of Sept 30, 2024 |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 31% year-over-year in Q3 and 80% for the nine-month period. The nine-month decline is primarily attributed to the cessation of revenue from the PRIME study with Elevance Health, which stopped enrollment in December 2023 due to efficacy.
- Operating Expenses: Total operating expenses decreased by approximately 13% for the nine months ended September 30, 2024, compared to the prior year. This reduction was driven by significant decreases in Selling and Marketing expenses ($3.5M decrease) and General and Administrative expenses ($0.6M decrease), largely due to headcount reductions and streamlined commercial strategies.
- Net Loss Improvement: While the company remains unprofitable, the net loss for the nine months ended September 30, 2024, decreased by $4.0 million compared to the same period in 2023, reflecting the reduction in operating costs.
- Investment Income: Other income, net, increased to $2.9 million for the nine months ended September 30, 2024, compared to $2.7 million in the prior year, driven by higher interest income on marketable securities.
Guidance, Outlook, and Risks
Outlook and Strategy: Management believes existing financial resources are sufficient to fund operations for at least the next 12 months. The company is focusing on commercializing the PreTRM test following positive data from the AVERT PRETERM TRIAL and the PRIME study. They have initiated real-world evidence programs expected to launch in late 2024 or early 2025. The company has filed a universal shelf registration (Form S-3) allowing for the sale of up to $100 million in securities and entered an at-the-market offering agreement for up to $50 million, though no shares have been sold under this agreement as of September 30, 2024.
Risks and Contingencies:
- Liquidity: The company has incurred net losses since inception and expects to continue doing so. Future operations depend on raising additional capital, which may be dilutive.
- Regulatory: The FDA issued a final rule in May 2024 to regulate Laboratory Developed Tests (LDTs). While currently marketed tests like PreTRM may have exemptions from premarket review initially, the company faces potential future compliance costs and regulatory burdens. Litigation challenging this rule is ongoing.
- Reimbursement: Revenue is heavily dependent on third-party payer reimbursement. The company faces risks related to coverage denials, billing disputes, and potential recoupments.
- Customer Concentration: The company relies on a limited number of direct customers, including Elevance Health, creating concentration risk.
Key Facts for Investor Verification
- Cash Runway: Verify the company's assertion that $74.3 million in liquid assets is sufficient to operate into 2027 based on current plans, given the continued burn rate.
- PRIME Study Results: Monitor the publication of final PRIME study results, expected in early 2025, as this data is critical for payer adoption and revenue growth.
- Regulatory Compliance: Track the implementation timeline of the FDA's LDT final rule and the outcome of pending litigation, as this could impact the commercialization of the PreTRM test.
- Capital Raising: Watch for any utilization of the new $50 million at-the-market offering program or other equity/debt financing activities.
- Revenue Recognition: Scrutinize the timing and volume of revenue recognition from the Commercial Collaboration Agreement with Elevance Health, as this remains a primary revenue driver.